Article
Immunology
Yixin Kang, Lu Xie, Jiyong Yang, Junchang Cui
Summary: This study evaluated the efficacy of ceftazidime-avibactam (CZA) and aztreonam-avibactam (AZA) against bloodstream infections (BSIs) or lower respiratory tract infections (LRTIs) caused by extensive drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa. The results showed that AZA can be used as a treatment option for infections caused by XDR/PDR P. aeruginosa producing IMP-45, VIM-1, or VIM-2. Optimized two-step-administration therapy (OTAT) with sufficient pharmacodynamic exposure may be the optimal treatment option for XDR/PDR P. aeruginosa with a high-level MIC of CZA/AZA.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Microbiology
Maria M. Montero, Sandra Domene Ochoa, Carla Lopez-Causape, Sonia Luque, Luisa Sorli, Nuria Campillo, Inmaculada Lopez Montesinos, Eduardo Padilla, Nuria Prim, Ariadna Angulo-Brunet, Santiago Grau, Antonio Oliver, Juan P. Horcajada
Summary: Ceftazidime-avibactam (CZA) has shown promise in treating Pseudomonas aeruginosa infections, particularly those that are extensively drug-resistant (XDR). Combination therapy with CZA and other antibiotics was more effective than monotherapy against XDR isolates, including those resistant to CZA. This study highlights the potential of CZA combinations in treating difficult-to-treat XDR P. aeruginosa infections.
MICROBIOLOGY SPECTRUM
(2021)
Article
Microbiology
Yulin Zhang, Jiankang Zhao, Jiajing Han, Yanyan Fan, Zhujia Xiong, Xiaohui Zou, Binbin Li, Xinmeng Liu, Ziyao Li, Binghuai Lu, Bin Cao
Summary: This study describes the genomic mechanism of resistance for ceftazidime-avibactam (CZA) nonsusceptible extensively drug-resistant Pseudomonas aeruginosa (XDRPA) strains. It also demonstrates the synergistic antibacterial activity of CZA-imipenem combination against non-MBL-producing XDRPA.
MICROBIOLOGY SPECTRUM
(2022)
Article
Microbiology
Thamer A. Almangour, Leen Ghonem, Dareen Alassiri, Alanoud Aljurbua, Mohammed Al Musawa, Aminah Alharbi, Abdullah Almohaizeie, Sara Almuhisen, Jeelan Alghaith, Nader Damfu, Doaa Aljefri, Wafa Alfahad, Yaqoub Khormi, Menyfah Q. Alanazi, Yazed Saleh Alsowaida
Summary: This study aimed to compare the effectiveness and safety of C-T and CAZ-AVI in treating infections caused by resistant P. aeruginosa. The results showed no significant differences between C-T and CAZ-AVI in terms of in-hospital mortality, 30-day mortality, clinical cure, and safety. Both drugs can be potential options for the treatment of MDR P. aeruginosa infections.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Inmaculada Lopez-Montesinos, Maria Milagro Montero, Sandra Domene-Ochoa, Carla Lopez-Causape, Daniel Echeverria, Luisa Sorli, Nuria Campillo, Sonia Luque, Eduardo Padilla, Nuria Prim, Santiago Grau, Antonio Oliver, Juan P. Horcajada
Summary: This study correlates the in vivo and in vitro findings of a patient with extensively drug-resistant P. aeruginosa infection, indicating a correlation between decreasing plasma levels of CAZ-AVI and the emergence of resistance. The study suggests that maintaining plasma CAZ-AVI levels at least 4 times the minimum inhibitory concentration (MIC) can prevent the development of resistance.
Article
Microbiology
Diego Faccone, Juan M. de Mendieta, Ezequiel Albornoz, Magali Chavez, Fabiana Genero, Mariano Echegorry, Paola Ceriana, Andrea Mora, Christine Seah, Alejandra Corso, Roberto G. Melano, Fernando Pasteran
Summary: A ceftazidime-avibactam-resistant KPC-producing Pseudomonas aeruginosa strain, belonging to the high-risk clone ST235/O11, was identified in Argentina. Whole-genome sequencing revealed a D179Y substitution in the Omega loop of KPC-3, corresponding to KPC-31 integrated at the chromosome. Most commonly used carbapenemase detection assays failed to identify the isolate as a KPC producer.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Microbiology
Yiwei Zhu, Jie Chen, Han Shen, Zhongju Chen, Qi-Wen Yang, Jin Zhu, Xi Li, Qing Yang, Feng Zhao, Jingshu Ji, Heng Cai, Yue Li, Linghong Zhang, Sebastian Leptihn, Xiaoting Hua, Yunsong Yu
Summary: Klebsiella pneumoniae carbapenemase (KPC)-producing Pseudomonas aeruginosa (KPC-PA) strains were found in 40.4% of carbapenem-resistant P. aeruginosa (CRPA) isolates, with half of them resistant to ceftazidime-avibactam (CAZ-AVI). Eight plasmid types and two mobile genetic elements mediating bla(KPC-2) transmission were identified through sequencing. Curing bla(KPC-2) plasmids in 28 strains restored CAZ-AVI susceptibility, indicating its role in resistance.
Review
Infectious Diseases
Sisi Zhen, Hui Wang, Sizhou Feng
Summary: CAZ-AVI is a valuable therapeutic option for MDR-GNB infections, particularly for KPC or OXA-48 CRE infections. It shows significant benefits and improved clinical outcomes, even in immunocompromised patients. Early use of CAZ-AVI is associated with better efficacy. However, resistance development in CRE and MDR-PA against CAZ-AVI is a concern, and further investigations are needed.
Article
Medicine, General & Internal
Tzu-Ting Chen, Shu-Mei Chen, Hsin-Yi Liu
Summary: Thoracic empyema and concomitant bronchopleural fistula are serious complications of pneumonia. This case report highlights the successful treatment of extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) empyema with ceftazidime-avibactam therapy, emphasizing the importance of source control.
Article
Immunology
Wei Yu, Luying Xiong, Qixia Luo, Yunbo Chen, Jinru Ji, Chaoqun Ying, Zhiying Liu, Yonghong Xiao
Summary: The study found that in vitro activity of aztreonam-avibactam was superior to ceftazidime-avibactam against carbapenem-resistant Escherichia coli and Klebsiella pneumoniae, while ceftazidime-avibactam showed better effect against carbapenem-resistant Pseudomonas aeruginosa.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Article
Microbiology
C. Weber, T. Schultze, S. Goettig, J. Kessel, A. Schroeder, M. Tietgen, S. Besier, T. Burbach, S. Haeussler, T. A. Wichelhaus, D. Hack, V. A. J. Kempf, M. Hogardt
Summary: The study demonstrates that cefiderocol is the most effective antipseudomonal beta-lactam agent for multidrug-resistant (MDR) Pseudomonas aeruginosa, with susceptibility rates of 46.6%, 48.4%, and 97.3% for ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol, respectively. The most prevalent sequence type was ST235 (24.7%), followed by ST244, ST175, and ST233, all of which belong to the top 10 high-risk clones with worldwide distribution. Surveillance studies should pay special attention to MDR and highly virulent VIM- and ExoU-producing variants of ST235. Cefiderocol is the preferred treatment option for infections caused by carbapenemase-producing MDR P. aeruginosa, and it has shown favorable outcomes in complicated urinary tract infections and hospital-acquired pneumonia.
MICROBIOLOGY SPECTRUM
(2022)
Review
Infectious Diseases
Alessandro Mancuso, Luca Pipito, Raffaella Rubino, Salvatore Antonino Distefano, Donatella Mangione, Antonio Cascio
Summary: BJIs caused by multidrug-resistant gram-negative bacteria are becoming a concern. Ceftazidime-avibactam has shown efficacy and safety in treating osteomyelitis and prosthetic joint infections, despite not being approved for these indications. This study presents three successful cases of resistant Pseudomonas aeruginosa osteomyelitis treated with ceftazidime-avibactam alone or in combination therapy.
Article
Microbiology
Pablo A. Fraile-Ribot, Javier Fernandez, Maria A. Gomis-Font, Lorena Forcelledo, Xavier Mulet, Carla Lopez-Causape, Antonio Oliver
Summary: The study investigated the mechanisms behind the in vivo switch in resistance phenotype of P. aeruginosa after ceftazidime-avibactam treatment. It was found that a single SNP difference can lead to a change in resistance profile, reverting a carbapenemase phenotype back into an ESBL phenotype. Through genetic analysis, it was discovered that certain mutations can alter the resistance patterns of bacteria in vivo.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Infectious Diseases
Raul Recio, Jennifer Villa, Sara Gonzalez-Bodi, Patricia Branas, Maria Angeles Orellana, Mikel Mancheno-Losa, Jaime Lora-Tamayo, Fernando Chaves, Esther Viedma
Summary: This study analyzed the phenotypic and genomic characteristics of ceftazidime/avibactam (CZA) resistance in different GES-producing Pseudomonas aeruginosa isolates. The results showed that all CZA-resistant isolates belonged to the ST235 clone and O11 serotype, and different mutations within the bla(GES)(-20) gene were associated with CZA resistance, suggesting the involvement of other resistance mechanisms.
Article
Infectious Diseases
Juan Chen, Qiqiang Liang, Xinyi Chen, Jing Wu, Yanchao Wu, Gaoqin Teng, Man Huang
Summary: This study compared the effectiveness of CAZ/AVI and polymyxin B in treating CRPA infection and analyzed the predictors of 30-day mortality or survival. The results showed that CAZ/AVI therapy was superior to polymyxin B therapy in terms of 14-day and 30-day mortality, in-hospital mortality, and bacterial clearance rate. Multivariate analysis also identified age, CAZ/AVI therapy, and central venous catheterization as independent predictors of 30-day mortality or survival.
INFECTION AND DRUG RESISTANCE
(2022)
Article
Immunology
Rodrigo Alonso-Navarro, Genoveva Cuesta, Marta Santos, Celia Cardozo, Veronica Rico, Nicole Garcia-Pouton, Montse Tuset, Marta Bodro, Laura Morata, Pedro Puerta-Alcalde, Sabina Herrera, Dafne Soria, Marta Aldea, Josep Mensa, Jose Antonio Martinez, Ana Del Rio, Jordi Vila, Felipe Garcia, Carolina Garcia-Vidal, M. Angeles Marcos, Alex Soriano
Summary: A prospective study found that negative subgenomic RNA (sgRNA) at admission or after 5 days of remdesivir therapy was associated with better outcomes in hospitalized patients with moderate/severe COVID-19. Monitoring sgRNA levels could be useful in assessing the response to antiviral treatment.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Orthopedics
Caribay Vargas-Reveron, Lluis Font-Vizcarra, Laura Morata, Jenaro A. Fernandez-Valencia, Alex Soriano, Ernesto Munoz-Mahamud
Summary: The association between unexpectedly positive culture results during elective hip arthroplasty and the risk of subsequent premature revision within 5 years is not known.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
(2023)
Article
Orthopedics
Ricardo Sousa, Ana Ribau, Pedro Alfaro, Marc-Antoine Burch, Joris Ploegmakers, Martin Mcnally, Martin Clauss, Marjan Wouthuyzen-Bakker, Alex Soriano
Summary: This study evaluated the diagnostic accuracy of the newly proposed definition of periprosthetic joint infection (PJI) by the European Bone and Joint Infection Society (EBJIS), comparing it with previous definitions and assessing its accuracy in preoperative diagnosis. The results showed that the EBJIS definition was the most sensitive and accurate in ruling out infection preoperatively.
Article
Medicine, General & Internal
George R. Thompson III, Alex Soriano, Oliver A. Cornely, Bart Jan Kullberg, Marin Kollef, Jose Vazquez, Patrick M. Honore, Matteo Bassetti, John Pullman, Methee Chayakulkeeree, Ivan Poromanski, Cecilia Dignani, Anita F. Das, Taylor Sandison, Peter G. Pappas
Summary: This study compared the efficacy and safety of intravenous rezafungin with intravenous caspofungin in the treatment of candidaemia and invasive candidiasis. The results showed that rezafungin was non-inferior to caspofungin in terms of efficacy and safety.
Article
Immunology
Berta Fidalgo, Laura Morata, Celia Cardozo, Ana del Rio, Javier Morales, Mariana Fernandez-Pittol, Jose Antonio Martinez, Josep Mensa, Jordi Vila, Alex Soriano, Climent Casals-Pascual
Summary: Rapid reporting of actionable microbiological results is critical for patient management, and delays in reporting this information to infectious diseases specialists are associated with an increased odds of death.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
S. Herrera, B. Torralbo, S. Herranz, J. Bernal-Maurandi, E. Rubio, C. Pitart, I. Fortes, S. Valls, L. Rodriguez, G. Santana, M. Bodro, C. Garcia-Vidal, M. Hernandez-Meneses, P. Puerta, L. Morata, A. Villella, M. J. Bertran, M. Brey, A. Soriano, A. Del Rio, J. A. Martinez
Summary: This study aimed to assess the impact of various factors on the duration of carriage of multidrug-resistant Gram-negative bacilli (MDR-GNB) and explore their application in infection control. The results showed that the colonization time of ESBL-KP, ESBL-non-E. coli Enterobacterales, OXA-48-KP, and MDR-PAER was significantly longer, and surveillance should be extended to 2.5-3 years for these microorganisms. Gender, clinical sample, multiple readmissions, admission service, and microbial type were independent predictors of carriage duration.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Patricia Monzo-Gallo, Mariana Chumbita, Carlos Lopera, Tommaso Francesco Aiello, Oliver Peyrony, Marta Bodro, Sabina Herrera, Abiu Sempere, Mariana Fernandez-Pittol, Genoveva Cuesta, Silvia Simo, Mariana Benegas, Claudia Fortuny, Josep Mensa, Alex Soriano, Pedro Puerta-Alcalde, Francesc Marco, Carolina Garcia-Vidal
Summary: We conducted a retrospective observational study to describe the epidemiology of invasive fungal infections (IFIs) and outcomes in hospitalized patients. A total of 367 IFIs were diagnosed, with candidemia and invasive aspergillosis being the most common types. Corticosteroid use and prior viral infection were identified as the main risk factors. The overall mortality rate at 12 weeks was 32.2%.
Article
Infectious Diseases
Sabina Herrera, Laura Morata, Abiu Sempere, Miguel Verdejo, Ana Del Rio, Jose Antonio Martinez, Guillermo Cuervo, Marta Hernandez-Meneses, Mariana Chumbita, Cristina Pitart, Pedro Puerta, Patricia Monzo, Carles Lopera, Francesco Aiello, Scarleth Mendoza, Carolina Garcia-Vidal, Alex Soriano, Marta Bodro
Summary: This study aimed to investigate the antimicrobial resistance of Pseudomonas aeruginosa (P. aeruginosa) in solid organ transplant (SOT) recipients. The results showed that hematologic malignancy and previous carbapenem therapy were associated with an increase in carbapenem-resistant P. aeruginosa bloodstream infections (BSIs). Age, urinary catheter, severity of infection, high-risk source, and bacteremia caused by carbapenem-resistant strains were associated with increased mortality. Correct empirical therapy was found to be a protective factor. The resistance of P. aeruginosa to carbapenems showed an increasing trend, with over 30% of isolates being resistant in the last period. SOT was not associated with a higher risk of carbapenem-resistant BSIs or higher mortality.
Article
Infectious Diseases
Alex Soriano, Philippe Montravers, Matteo Bassetti, Galina Klyasova, George Daikos, Paurus Irani, Gregory Stone, Richard Chambers, Pascale Peeters, Mitesh Shah, Claire Hulin, Natalia Albuquerque, Efim Basin, Benjamin Gaborit, Irene Kourbeti, Francesco Menichetti, Maria Teresa Perez-Rodriguez, Mathias W. Pletz, Marisa Sanchez, Ivan Trompa, Anita Verma, Maria Lavinea N. de Figueiredo, Claudie Charbonneau
Summary: This study describes the patterns of use, effectiveness, and safety of ceftazidime-avibactam in real-world clinical practice. Despite the presence of multidrug-resistant bacteria, ceftazidime-avibactam achieved a treatment success rate of 77.3%. The findings of this study provide real-world evidence for the use of ceftazidime-avibactam.
INFECTIOUS DISEASES AND THERAPY
(2023)
Article
Orthopedics
Marta Sabater-Martos, Miguel A. Verdejo, Laura Morata, Ernesto Munoz-Mahamud, Ernesto Guerra-Farfan, Juan C. Martinez-Pastor, Alex Soriano
Summary: In this article, the principles and limitations of local antibiotic delivery are reviewed, with a focus on the potential association between antibiotic-loaded bone cement (ALBC) and antimicrobial resistance. The efficacy of ALBC for prosthetic joint infection (PJI) prophylaxis and treatment is discussed, and concerns regarding the emergence of resistance are addressed. The current evidence does not support an association between the use of ALBC and increased antimicrobial resistance.
Article
Immunology
Tobias Siegfried Kramer, Alex Soriano, Sarah Tedeschi, Antonia F. Chen, Pierre Tattevin, Eric Senneville, Joan Gomez-Junyent, Victoria Birlutiu, Sabine Petersdorf, Vicens Diaz de Brito, Ignacio Sancho Gonzalez, Katherine A. Belden, Marjan Wouthuyzen-Bakker
Summary: Combination treatment with rifampicin increases treatment success in patients with chronic staphylococcal PJI treated with 2-stage exchange arthroplasty.
OPEN FORUM INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Carmen Hidalgo-Tenorio, Ines Pitto-Robles, Daniel Arnes Garcia, F. Javier Membrillo de Novales, Laura Morata, Raul Mendez, Olga Bravo de Pablo, Vicente Abril Lopez de Medrano, Miguel Salavert Lleti, Pilar Vizcarra, Jaime Lora-Tamayo, Ana Arnaiz Garcia, Leonor Moreno Nunez, Mar Masia, Maria Pilar Ruiz Seco, Svetlana Sadyrbaeva-Dolgova
Summary: This study analyzed the use of ceftobiprole medocaril (Cefto-M) in Spanish clinical practice, primarily for respiratory and skin and soft tissue infections, as rescue therapy in severe infectious diseases. Age, ICU admission, and sepsis/septic shock were identified as factors associated with higher mortality rates.
Meeting Abstract
Infectious Diseases
A. Soriano, G. R. Thompson III, O. A. Cornely, B. J. Kullberg, M. Kollef, J. Vazquez, P. M. Honore, M. Bassetti, J. Pullman, C. Dignani, A. F. Das, T. Sandison, P. G. Pappas
JAC-ANTIMICROBIAL RESISTANCE
(2023)
Article
Infectious Diseases
Christen Ravn, Jeroen Neyt, Natividad Benito, Miguel Araujo Abreu, Yvonne Achermann, Svetlana Bozhkova, Liselotte Coorevits, Matteo Carlo Ferrari, Karianne Wiger Gammelsrud, Ulf-Joachim Gerlach, Efthymia Giannitsioti, Martin Gottliebsen, Nis Pedersen Jorgensen, Tomislav Madjarevic, Leonard Marais, Aditya Menon, Dirk Jan Moojen, Markus Paakkonen, Marko Pokorn, Daniel Perez-Prieto, Nora Renz, Jesus Saavedra-Lozano, Marta Sabater-Martos, Parham Sendi, Staffan Tevell, Charles Vogely, Alex Soriano
Summary: This guideline provides evidence and opinion-based recommendations for the diagnosis and management of patients with septic arthritis of a native joint. It is intended for use by orthopedic surgeons and physicians who care for these patients.
JOURNAL OF BONE AND JOINT INFECTION
(2023)
